The immune system usually develops antibodies and T cells that attack microbes or tumors but not our own cells or organs. However, there are circumstances where the immune system generates T cells that react and assault our own antigens and tissues. This reactivity against self could evolve into an abrupt reaction and lead to severe autoimmune disease. The long term objective of this proposal is to develop a strategy to calm the autoaggressive T cells and reverse the disease. The model system to be used to test the strategy is experimental autoimmune encephalomyelitis (EAE), a T cell mediated inflammatory and demyelinating disease of the central nervous system (CNS) that is used as an animal model for human multiple sclerosis (MS). In both EAE and human MS T cells infiltrate the CNS and upon recognition of the myelin proteins within the brain produce protein hormones or cytokines that attract inflammatory cells capable of destroying the myelin sheath that covers and protects the axons. A logical approach to treat this disease is to inactivate or reprogram the myelin reactive T cells to halt production of inflammatory cytokines. Peripheral and non-activated antigen presenting cells (APCs) express minimal or no costimulatory molecules. In consequence presentation of antigen by such APCs leads to T cell unresponsiveness. The strategy of antigen injection in the absence of costimulatory activation is being considered as a useful approach to turn off autoreactive T cells involved in autoimmunity. In addition, since T cells are flexible in the way that they recognize antigens it is possible to slightly modify the composition of antigen to generate altered forms that are recognizable by the T cells but could shut off the cell or reprogram the cytokine production. In this application we propose to test a vehicle strategy to deliver self and altered- self peptides in a manner that could effectively modulate the autoreactive T cells and possibly improve the disease. In this strategy wild type and modified myelin peptides will be genetically incorporated into immunoglobulins (Igs) and the resulting Ig-myelin chimeras will be injected into sick mice without adjuvant (no costimulation) to test for amelioration of the disease. We have evidence that Igs function as an efficient peptide delivery system and are endowed with the capability to promote the modulator function of altered peptides. Therefore, our hypothesis is that delivery of self and altered self peptides by Igs maybe an efficient strategy to ameliorate T cell mediated autoimmune disease involving multiple autoantigens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS037406-02
Application #
6343888
Study Section
Special Emphasis Panel (ZRG1-BDCN-4 (01))
Program Officer
Utz, Ursula
Project Start
2000-01-01
Project End
2001-07-31
Budget Start
2001-01-01
Budget End
2001-07-31
Support Year
2
Fiscal Year
2001
Total Cost
$108,880
Indirect Cost
Name
University of Tennessee Knoxville
Department
Microbiology/Immun/Virology
Type
Schools of Arts and Sciences
DUNS #
City
Knoxville
State
TN
Country
United States
Zip Code
37996
Olanow, C Warren; Kieburtz, Karl; Odin, Per et al. (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141-9
Amara, Amy W; Standaert, David G (2013) Metabolomics and the search for biomarkers in Parkinson's disease. Mov Disord 28:1620-1
Yokoi, Fumiaki; Dang, Mai T; Zhou, Tong et al. (2012) Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models. Hum Mol Genet 21:916-25
Divekar, Rohit D; Haymaker, Cara L; Cascio, Jason A et al. (2011) T cell dynamics during induction of tolerance and suppression of experimental allergic encephalomyelitis. J Immunol 187:3979-86
Zhang, Jinping; Lee, Sang-Myeong; Shannon, Stephen et al. (2009) The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 119:3048-58
Yu, Ping; Haymaker, Cara L; Divekar, Rohit D et al. (2008) Fetal exposure to high-avidity TCR ligand enhances expansion of peripheral T regulatory cells. J Immunol 181:73-80
Bell, J Jeremiah; Ellis, Jason S; Guloglu, F Betul et al. (2008) Early effector T cells producing significant IFN-gamma develop into memory. J Immunol 180:179-87
Bell, J Jeremiah; Divekar, Rohit D; Ellis, Jason S et al. (2008) In trans T cell tolerance diminishes autoantibody responses and exacerbates experimental allergic encephalomyelitis. J Immunol 180:1508-16
Yu, Ping; Gregg, Randal K; Bell, J Jeremiah et al. (2005) Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol 174:6772-80
Bell, J Jeremiah; Min, Booki; Gregg, Randal K et al. (2003) Break of neonatal Th1 tolerance and exacerbation of experimental allergic encephalomyelitis by interference with B7 costimulation. J Immunol 171:1801-8

Showing the most recent 10 out of 13 publications